|
 |
MultihanceThis page contains recent news articles, when available, and an overview of Multihance but does not offer medical advice. You should contact your physician with regard to any health issues or concerns....including GE Healthcare (Omniscan), Bayer Healthcare (Magnevist), Bracco Diagnostics (MultiHance and ProHance) and Covidien (Optimark). ... AboutLawsuits.com FDA Requests Boxed Warning for Contrast Agents Used to Improve MRI … - May 23, 2007 NSF also has developed after the sequential administration of Omniscan and MultiHance and Omniscan and ProHance. Because reports incompletely describe ... DG News Imaging; FDA approval clears the way for addition of new MRI agent - Feb 27, 2005 Unlike other paramagnetic contrast agents, MultiHance demonstrates weak and ... The addition of MultiHance to the array of Bracco Diagnostics products now ... Pay-Per-View - Medical Devices & Surgical Technology... - Factiva, from Dow Jones MultiHance for MR Angiography approved in Europe - Mar 10, 2007 Bracco Imaging announces that the MR Angiography indication for MultiHance has been approved by the EU member states via a mutual recognition procedure. ... European Hospital Q1 2005 EPIX Pharmaceuticals, Inc. Earnings Conference Call - Final. - Apr 28, 2005 In addition, we have no basis for forecasting Multihance uptake in the US in the midst of its product launch. At present, as a result of the relevant patent ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Federal Register 2006 - 71 FR 39120 Determination of Regulatory … - Jul 11, 2006 FDA recently approved for marketing the human drug product MULTIHANCE ... MULTIHANCE is indicated for intravenous use in magnetic resonance imaging (MRI) of ... Pay-Per-View - Federal Register 2006 - Loislaw Results from the Largest Ever CNS MR Crossover Investigation Published... - Aug 1, 2006 Half of the patients received MultiHance for their first exam and the ... Bracco received FDA approval to market MultiHance in the USA in November 2004. ... $4.95 - Business Wire - ECNext Imaging; FDA approval clears the way for addition of new MRI agent - Feb 21, 2005 Unlike other paramagnetic contrast agents, MultiHance demonstrates weak and ... The addition of MultiHance to the array of Bracco Diagnostics products now ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Imaging; FDA approval clears the way for addition of new MRI agent - Feb 26, 2005 Unlike other paramagnetic contrast agents, MultiHance demonstrates weak and ... The addition of MultiHance to the array of Bracco Diagnostics products now ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Bracco Diagnostics Inc. And HealthTrust Purchasing Group Sign a Three... - Oct 5, 2007 MultiHance is a MRI contrast agent. Bracco launched MultiHance in Europe in ... Unlike other paramagnetic contrast agents, MultiHance demonstrates weak and ... RedOrbit Blood Brain Barrier; Contrast agent for central nervous system gets... - Jan 8, 2005 FDA approval of MultiHance expands Bracco Diagnostics' product portfolio within ... MultiHance is indicated for use in MRI of the central nervous system in ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Blood Brain Barrier; Contrast agent for central nervous system gets... - Jan 3, 2005 FDA approval of MultiHance expands Bracco Diagnostics' product portfolio within ... MultiHance is indicated for use in MRI of the central nervous system in ... Pay-Per-View - Clinical Trials Week - Factiva, from Dow Jones Blood Brain Barrier; Contrast agent for central nervous system gets... - Jan 4, 2005 FDA approval of MultiHance expands Bracco Diagnostics' product portfolio within ... MultiHance is indicated for use in MRI of the central nervous system in ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Q4 2004 EPIX Pharmaceuticals, Inc. Earnings Conference Call - Final. - Feb 17, 2005 First, MultiHance was approved by the FDA in the US in late November. Under terms of our license agreement with Bracco for MultiHance, this gave rise to a ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com FDA Requests Boxed Warning For Contrast Agents Used To Improve MRI … - May 30, 2007 NSF also has developed after the sequential administration of Omniscan and MultiHance and Omniscan and ProHance. Because reports incompletely describe ... Medical News Today - Medical News Today (press release) FDA wants 'black box' warnings for certain MRI contrast agents - May 31, 2007 NSF also has developed after the sequential administration of Omniscan and MultiHance and Omniscan and ProHance. Because reports incompletely describe ... Free with registration - Diagnostic Update - AccessMyLibrary.com RADIO REVIEW BY BARRY DIDCOCK - Nov 23, 2008 We were introduced to "emoti-news", which seeks to "enwiden and multihance" our enjoyment of the news, and to a complaint from a listener about the ... Pay-Per-View - Sunday Herald - ProQuest Archiver Gadolinium-containing contrast agents and nephrogenic systemic... - Mar 22, 2006 Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, Pro-Hance, and MultiHance. Public Health Advisory ... Free with registration - WHO Drug Information - AccessMyLibrary.com MR contrast, renal dermopathy linked.(Clinical Rounds)(magnetic … - Feb 1, 2007 Currently, there are five FDA-approved gadolinium-based contrast agents: Magnevist, MultiHance, Omniscan, Opti-MARK, and ProHance. These contrast agents are ... Free with registration - Skin & Allergy News - AccessMyLibrary.com MR contrast tied to skin syndrome.(News)(magnetic resonance) - Jan 15, 2007 The FDA has approved five gadolinium-based contrast agents--Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance--all for use during an MRI scan, ... $4.95 - Internal Medicine News - ECNext Bracco Diagnostics, Inc.(Company News) - Apr 1, 2005 MultiHance is designed for use in the MRI of the central nervous system of adults to visualize lesions with abnormal blood brain barriers or abnormal ... Free with registration - Spectroscopy - AccessMyLibrary.com In renal disease patients, think twice before MRI: nephrogenic... - Sep 1, 2007 Because nonionic Omniscan and Optimark have a far lower conditional stability constant than do Magnevist, Multihance, and Prohance at normal body pH, ... $4.95 - Skin & Allergy News - ECNext Progressive arm and leg stiffness in a patient with chronic renal … - Feb 5, 2008 Five of these exams included gadolinium-containing contrast media (total dose 105 ml of MultiHance ® [Bracco International BV, Amsterdam, The Netherlands] ... Nature.com Article: AAA, Bracco's offers free rides New Year's Eve. - Dispatch... - Jan 2, 2006 Article: Bracco Diagnostics' MultiHance Earns FDA Approval; MRI ... ... FDA approval of MultiHance expands Bracco Diagnostics' product portfolio within ... Pay-Per-View - The Dispatch - HighBeam Research Finance; Maker of MRI pharmaceuticals reports dip in net losses for … - Mar 25, 2005 EPIX recently received correspondence from Bracco in which Bracco indicated that it had overstated non-US Multihance royalties to EPIX for the period ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Gadolinium MRI Contrast Agent Health Risk Alert Issued - Oct 23, 2008 MultiHance (gadobenate dimeglumine) manufactured by Bracco Diagnostics, Inc. It is unknown if the risk for developing NSF is the same for all agents. ... TransWorldNews - TransWorldNews (press release) NSF NFD Gadolinium Lawyers offer Nationwide Assistance to Patients - Jan 17, 2008 Magnevist (gadopentetate dimeglumine), Ominiscan (gadodiamide); OptiMARK (gadoversetamide); MultiHance;(gadobenate dimeglumine);and Prohance (gadoteridol). Press Media Wire - Press Media Wire (Press Release) High-Dose Gadolinium May Be Linked to NSF/NFD in Patients with Renal … - Jun 9, 2006 Inc), Magnevist (made by Berlex Laboratories, Inc), ProHance (made by Bracco Diagnostics, Inc), and MultiHance (made by Bracco Diagnostics, Inc). ... Medscape FDA Issues Alert on Gadolinium-Based Contrast Agent for Kidney … - Dec 22, 2006 There are five FDA-approved gadolinium-based contrast agents, Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. These contrast agents are FDA ... MedPage Today Article: Gadolinium and kidney disease: are your patients at risk?(Cli... - Mar 1, 2008 ...gadoversetamide (OptiMARK[R]), gadopentetate dimeglumine (Magnevist[R]), gadoteridol (ProHance[R]), and gadobenate dimeglumine (MultiHance[R]). ... Pay-Per-View - Nephrology Nursing Journal - HighBeam Research Floundering fortunes: few specialty journal markets emerged from last... - May 1, 2006 Newly advertised Multihance Diagnostic X-Ray Media from Bracco Diagnostics was 2nd, while NEC MD Series Displays jumped from 69th to 3rd after increasing ad ... Free with registration - Medical Marketing & Media - AccessMyLibrary.com Infection may increase risks from contrast agents: researchers... - May 15, 2008 ...gadolinium-based contrast agents, but there is reason to believe ... approved gadolinium-based contrast agents: Magnevist, MultiHance, Omniscan ... ... Pay-Per-View - Family Practice News - HighBeam Research Gadolinium Exposure Independently Linked to NFD - Feb 23, 2007 OptiMARK (Mallinckrodt, Inc), Magnevist (Berlex Laboratories, Inc), ProHance (Bracco Diagnostics, Inc), and MultiHance (Bracco Diagnostics, Inc). ... Medscape Use of Gadolinium in MRI and MRA Linked to NSF/NFD in Patients With... - Jan 2, 2007 OptiMARK, Magnevist, ProHance [made by Bracco Diagnostics, Inc], and MultiHance [made by Bracco Diagnostics, Inc]) are approved for use in MRA. ... Medscape MRA contrast selection expands with new compounds - Feb 1, 2006 ...(gadopentate or Gd-DTPA, Schering), Omniscan (gadodiamide or Gd-DTPA-BMA, GE Healthcare), and Multihance (gadopentate dimeglumine or Gd-BOPTA, Bracco). ... Pay-Per-View - Diagnostic Imaging - Factiva, from Dow Jones Producenter af farlige kontrastmidler sagsøges for milliarder af... - Feb 29, 2008 Der er fem gadoliniumholdige kontrastmidler godkendt i USA af FDA - Omniscan, Magnevist, Optimark, Multihance og Prohance. ... Dagens Medicin Gadolinium-based MRI Contrast Agents Linked to Potentially Fatal … - Jul 4, 2007 Magnevist (gadopentetate dimeglumine), Ominiscan (gadodiamide); OptiMARK (gadoversetamide); MultiHance;(gadobenate dimeglumine);and Prohance (gadoteridol). prweb.com FDA ISSUES SAFETY ALERT FOR MRI CONTRAST REAGENTS - Jun 12, 2006 The products in question include Omniscan, OptiMARK, Magnevist, ProHance and MultiHance. The agency is evaluating safety issues related to ... Pay-Per-View - FDAnews Device Daily Bulletin - Factiva, from Dow Jones FDA wil aanpassing gebruik contrastvloeistoffen bij nierziekte - Aug 25, 2008 De minste risico's zijn verbonden aan het gebruik van Prohance, dat ook hier beschikbaar is, en Multihance, allebei van Bracco Diagnostics. ... NierNieuws.nl FDA Warns Doctors About Gadolinium-Based Contrast Agents - May 25, 2007 Some of the companies that provide gadolinium-based MRI dyes to radiologists include: Magnevist, MultiHance, ProHance, Omniscan, and OptiMARK. ... US Recall News - US Recall News (press release) Medicare Part D looms; ongoing fallout from Vioxx - Jul 21, 2005 Multihance. Gadobenate Dimeglumine. Bracco. S. 11/23/04. VESIcare. Solifenacin Succinate. Yamanouchi. S. 11/19/04. Tarceva. Erlotinib Hydrochloride ... $295.00 - Industry Surveys - Standard & Poor's Bracco Diagnostics in imaging agent accord with HealthTrust - Oct 11, 2007 This agreement includes MultiHance (gadobenate dimeglumine) injection, 529 mg/mL and ProHance (gadoteridol) injection 279.3 mg/mL. ... Free with registration - Diagnostic Update - AccessMyLibrary.com Article: Affymetrix System Cleared by FDA. - Analytic Separations... - Jan 1, 2005 MultiHance, which received U.S. Food & Drug Administration (FDA) marketing approval in November 2004, is indicated for use ... evidenced by our research, ... Pay-Per-View - Analytic Separations News - HighBeam Research MRI Contrast Agents May Pose Risk for Patients With Kidney Disease - Jan 17, 2007 So far, no cases have been reported with patients taking gadoteridol (ProHance) or gadobenate dimeglumine (MultiHance). Kanal does not know if absence of ... Journal of American Medical Association - Journal of American Medical Association... NSF: A New Concern for ESRD Patients - Oct 22, 2007 A total of five GBCA (Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance) are currently approved for use in the United States . ... Renal and Urology News Contrast Agent Linked to Fibrosing Disorder in Dialysis Patients - Oct 1, 2007 The agents are magnevist (gadopentetate dimeglumine) injection, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, Omniscan (gadodiamide) injection, ... MedPage Today MR contrast agent poses danger in renal disease.(Clinical Rounds) | … - Feb 1, 2007 Currently, there are five FDA-approved gadolinium-based contrast agents: Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. These contrast agents are ... Pay-Per-View - Pediatric News - HighBeam Research Press Release: Gadolinium-based MRI Contrast Agents Linked to … - Jul 3, 2007 ...(gadopentetate dimeglumine), Ominiscan (gadodiamide); OptiMARK (gadoversetamide); MultiHance;(gadobenate dimeglumine); and Prohance (gadoteridol). ... Pay-Per-View - PR Newswire - HighBeam Research Contrast agents may pose danger in renal disease.(Clinical Rounds)( … - Feb 1, 2007 Currently, there are five FDA-approved gadolinium-based contrast agents: Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. These contrast agents are ... Pay-Per-View - Family Practice News - HighBeam Research FDA call for warning on contrast agents.(Brief article) - Jun 4, 2007 ...(gadopentetate dimeglumine), Ominiscan (gadodiamide); OptiMARK (gadoversetamide); MultiHance; (gadobenate dimeglumine); and Prohance (gadoteridol). $4.95 - Pharma Marketletter - ECNext Bracco and Health Trust in contrast media deal. - Oct 15, 2007 This agreement includes MultiHance (gadobenate dimeglumine) injection, 52mg/mL and ProHance (gadoteridol) injection 279.3mg/mL. ... $4.95 - Pharma Marketletter - ECNext FDA: boxed warning per i mezzi di contrasto a base di Gadolinio - Nov 12, 2007 I prodotti interessati al provvedimento sono: Magnevist della Bayer, MultiHance della Bracco, Omniscan della GE Healthcare, OptiMARK della Mallinckrodt e ... XagenaSalute Rischio di fibrosi sistemica nefrogenica con i mezzi di contrasto … - Oct 9, 2007 Negli Stati Uniti sono stati approvati 5 mezzi di contrasto: Magnevist, MultiHance, Omniscan, OptiMark e ProHance. La fibrosi sistemica nefrogenica, ... XagenaSalute 간종양 진단·ê°?별위해 ì ?ì ˆí•œ ì˜?ìƒ?기법 ì„ íƒ? 중요 - Feb 8, 2007 MRIì?˜ 경우 ì?¼ë°˜ì ?으로 사용하는 Gadolinium-enhanced MRI외ì—? 간특ì?´ ì¡°ì˜?ì œì?¸ Superparamagnetic iron oxide (SPIO)-enhanced MRI와 Gd-BOPTA(ìƒ?품명; MultiHance)- ... 디지틀보사 FDA: Warnhinweise für gadoliniumhaltige Kontrastmittel - May 24, 2007 ...hat die US-Behörde für alle fünf Kontrastmittel (neben Omniscan® noch Magnevist®, MultiHance®, OptiMARK® und ProHance®) Warnungen verfügt. ... Deutsches Ärzteblatt Fibrosi nefrogenica sistemica dopo somministrazione dei mezzi di … - Nov 9, 2007 I mezzi di contrasto autorizzati in Canada sono: Magnevist, Omniscan, OptiMARK, Gadovist, ProHance, MultiHance e Vasovist. La fibrosi sistemica nefrogenica, ... XagenaSalute ì‹ ìž¥ì„± ì„¬ìœ í”¼ë¶€ì§ˆí™˜ì?¸ NSFë°œìƒ?위험 ë³´ê³ ë”°ë?¼ - Oct 4, 2007 ...마린í?¬ë¡œíŠ¸ì‚¬ì?˜ OptiMark(gadoversetamide) 브로코 진단회사ì?˜ MultiHance(gadobenate dimeglumine) ë°? ProHance(gadoteridol) 등ì?´ ì‹œíŒ?ë?˜ê³ 있다. ... 메디í?¬ë‰´ìŠ¤ Nephrogenic Fibrosing Dermopathy Associated with Exposure to … - Feb 23, 2007 Public health advisory: gadoliniumcontaining contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. ... Pay-Per-View - MMWR. Morbidity and Mortality Weekly... - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |